FDA Extends Protection For Salix Drug
Posted August 29, 2006
RALEIGH, N.C. — Salix Pharmaceuticals'
protection against generic competition for its ulcerative colitis drug for young people ages 5-17 has been extended through Jan. 8, 2007, by the Food and Drug Administration.
Salix had sought the additional marketing exclusivity for Colazal in June.